Summit Therapeutics Reports Ivonescimab Survival Data at WCLC
Los Angeles, California, September 15, 2026 Summit Therapeutics has announced positive overall survival results from the Phase 3 HARMONi-2...
Summit Therapeutics
Advertisement
Summit Advances Ivonescimab in Global HARMONi Trial
August 25, 2026 | Miami, Florida, USA Summit Therapeutics Inc. has announced the publication of primary analysis results from...
Obsidian Therapeutics Enrolls First Patient in Registration-Enabling Agni-01 Melanoma Trial
CAMBRIDGE, Mass., August 5, 2026 Obsidian Therapeutics announced the enrollment of the first patient in the registration-enabling cohort of...
Summit Therapeutics Launches Global Phase 3 Ivonescimab Trial in Bladder Cancer
MIAMI, August 5, 2026 Summit Therapeutics announced the launch of the Phase II/III HARMONi-GU1 study, the company’s first global...
Advertisement
